Almirall + Nuevolution = Fighting together inflammatory skin diseases

Published on 20/03/2017

Almirall S.A. and Nuevolution A/S have entered into a global strategic collaboration focusing on the development and commercialization of Nuevolution's novel RORγt inverse agonist (inhibitor) program for treatment of inflammatory...

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our policy of cookies, click on the link for more information.

Aviso de cookies